Fund+
People
- Board members
- Our team
Investment Strategy
Portfolio
- Current
- Exits
Your Project
News
Contact us

Immunic

Immunic Press Release

2022-08-17

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States…

Immunic Press Release

2022-07-07

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

Immunic, Inc. Strengthens Its Board…

Immunic Press Release

2022-05-05

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic Announces Start of Patient…

Immunic Press Release

2022-02-24

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

– Initiated Enrollment in Phase…

Immunic Press Release

2021-12-14

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

- Unblinded Data Established a…

Immunic Press Release

2021-12-10

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

NEW YORK, Dec. 9, 2021…

Immunic Press Release

2021-11-22

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

NEW YORK, Nov. 18, 2021…

Immunic Press Release

2021-11-04

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

– Fully Enrolled Phase 2…

Immunic Press Release

2021-10-28

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

– Top-Line Data Expected…

Immunic Press Release

2021-10-15

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

NEW YORK, Oct. 14, 2021…

1
2
3
4

Contact us

Address:
Groot Begijnhof 60
3000 Leuven
Belgium
Phone: +32 (0)16 90 50 00
Email: info@fundplus.be

Recent Articles

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
Fund+ Portfolio Company Tubulis to be Acquired by Gilead
TargED Biopharmaceuticals to Present First Clinical and New Preclinical Data on TGD001 in Two Oral Sessions at the 2025 ASH Annual Meeting

© 2019 FUND⁺- ALL RIGHTS RESERVED. |

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT Read More

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT